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Analysis of a genome screen of 504 brothers with prostate cancer (CaP) who were from 230 multiplex sibships
identified five regions with nominally positive linkage signals, on chromosomes 2q, 12p, 15q, 16p, and 16q. The
strongest signal in these data is found on chromosome 16q, between markers D16S515 and D16S3040, a region
suspected to contain a tumor-suppressor gene. On the basis of findings from previous genome screens of families
with CaP, three preplanned subanalyses were carried out, in the hope of increasing the subgroup homogeneity.
Subgroups were formed by dividing the sibships into a group with a positive family history (FH+) that met criteria
for “hereditary” CaP ( ) versus those which did not meet the criteria ( ) and by dividing the familiesn = 111 n = 119
into those with a mean onset age below the median ( ) versus those with a mean onset age above the mediann = 115
( ). A separate subanalysis was carried out for families with a history of breast cancer (CaB+ [ ]).n = 115 n = 53
Analyses of these subgroups revealed a number of potentially important differences in regions that were nonsig-
nificant when all the families were analyzed together. In particular, the subgroup without a positive family history
(FH5) had a signal in a region that is proximal to the putative site of the HPC1 locus on chromosome 1, whereas
the late-age-at-onset group had a signal on 4q. The CaB+ subgroup revealed a strong linkage signal at 1p35.1.
Introduction
This year, prostate cancer (CaP) will be the most com-
monly diagnosed visceral cancer and the second leading
cause of cancer mortality among men in the United
States (Landis et al. 1999). The prevalence of CaP varies
20- to 30-fold worldwide. The highest frequency is
found in African Americans, and the lowest frequency
is found in Asian populations (Parkin et al. 1993; Whit-
temore 1994). Although immigrant (Staszewski and
Haenszel 1965; Dunn 1975) and lifestyle and dietary
studies (Whittemore et al. 1995a) point to the impor-
tance of environmental factors, twin (Gro¨nberg et al.
1994; Ahlbom et al. 1997), “kinship” (Cannon et al.
1982; Holloway and Sofaer 1992a, 1992b), and family
studies (Morganti et al. 1956; Woolf 1960; Steele et al.
1971; Krain 1974; Meikle et al. 1985; Steinberg et al.
1990; Ghadirian et al. 1991; Spitz et al. 1991; Keetch
et al. 1995; Whittemore et al. 1995b) point to the im-
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portance of genetic factors. The two strongest predictors
of increased risk for CaP, apart from age, are the pres-
ence of several affected first-degree relatives and an af-
fected brother who had an unusually early age at onset
(Keetch et al. 1995).
Segregation analysis has suggested that some cases of
CaP are due to an autosomal susceptibility locus with
an allele or alleles that collectively behave in a dominant
and age-dependent fashion (Carter et al. 1992; Gro¨n-
berg et al. 1997a; Schaid et al. 1998). Other investi-
gators have argued either for a recessive mode of in-
heritance or, on the basis of an excess risk of CaP in
men with affected brothers compared with men with
affected fathers, for an X-linked mode of transmission
(Monroe et al. 1995). Unlike breast cancer (Miki et al.
1994; Tavtigian et al. 1996) or colorectal cancer (Fearon
et al. 1990; Groden et al. 1991), however, no suscep-
tibility loci with alleles sufficient to cause CaP have yet
been identified.
We report here the results of a genome screen of 230
multiplex sibships with CaP.
Families and Methods
Families
Since 1991, we have been collecting information
about multiplex sibships with CaP. No ascertainment
criteria, other than the presence of two or more brothers
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with documented CaP and a willingness to participate,
have been used to recruit the members of the sample
population. Approximately half of these subjects were
patients of Washington University School of Medicine
(WUSM) staff urologists, were referred by other urol-
ogists or CaP support groups, or responded to our
publications soliciting participation. The remainder were
referred by family members enrolled in our studies. The
study protocol was approved by the Human Studies
Committee of Washington University. Informed consent
was obtained from all subjects. All probands and many
of their affected brothers completed a family-history
questionnaire that was used to partition the sample for
various preplanned subanalyses.
A total of 513 subjects were genotyped. Subsequent
analyses (see below) reduced this sample to 504 men
with CaP. The subjects’ mean age at the time of diagnosis
was 65.5 years (median, 65.4 years; range, 42–91 years).
The diagnosis of CaP was confirmed directly by
WUSM pathologists or by examination of the medical
records in 502 (99.6%) of the subjects. Pathologic doc-
umentation was missing from two subjects (0.4%); how-
ever, in these subjects, the diagnosis of CaP was affirmed
by treatment records.
Seventy-six percent of the patients were treated pri-
marily with radical prostatectomy, 10.3% were treated
with radiation therapy, 2.6% were treated with primary
hormonal therapy, 2.6% were managed with watchful
waiting, and 8.5% received miscellaneous other treat-
ments. Of the patients treated primarily with radical
prostatectomy, 15.1% have also been treated with hor-
monal therapy and 7.8% have been treated with radi-
ation therapy.
Genotyping
All samples were genotyped at the Center for Medical
Genetics, Marshfield Medical Research Foundation, by
use of Weber screening set 9 (Yuan et al. 1997), which
consists of simple tandem-repeat polymorphisms, in-
cluding 366 autosomal, 16 X-linked, and 4 Y-linked
markers. Average marker heterozygosity was 77%, and
average spacing on sex-equal maps was 9 cM (Broman
et al. 1998).
A multipoint linkage analysis (see below) was used to
rank the markers according to the estimated mean allele
sharing among affected brothers. Regions around the
highest-ranking nine markers were selected for further
genotyping. An additional 38 microsatellite markers
(∼4.2/signal) were genotyped at the Center for Medical
Genetics, Marshfield Medical Research Foundation. The
average spacing between adjacent markers for the 38
new intervals created by this second wave of genotyping
was 2.2 cM.
Statistical Methods
Before conducting the linkage analysis, we assessed
the marker genotypes to verify the status of each alleged
sib pair, using two approaches: the RELATIVE program
(Go¨ring and Ott 1995) and a modified version of the
RELPAIR program (Boehnke and Cox 1997; Broman
and Weber 1998). The results were similar with both
programs and revealed the presence of one half-sib (from
an affected trio) and four sets of twins (one pair of which
was from an affected trio) who, by genotyping, were
shown to be MZ. An additional subject was dropped
from the affected sample after the genome screen had
been completed because a record review indicated that
he did not have CaP. After these nine individuals had
been deleted from the sample, 504 full sibs from 230
nuclear families remained for linkage analysis. The fa-
milial distribution of genotyped brothers used in this
analysis was as follows: 188 affected pairs, 40 affected
trios, and 2 affected quartets.
To determine if alleles at the microsatellite markers
were in Hardy-Weinberg proportions in this sample, we
carried out likelihood-ratio tests with the ASSOC pro-
gram (Ott 1985), choosing, from each family at random,
one genotyped sib per marker.
Despite the evidence from three separate segregation
analyses—all of which argue that a sizable proportion
of CaP cases (particularly early-onset cases) are due to
a highly penetrant dominant gene—a susceptibility locus
has not yet been identified. Therefore, rather than com-
pute linkage statistics under what may eventually prove
to be a grossly inaccurate model, we preferred to com-
pute allele-sharing statistics that do not require specifi-
cation of the mode of transmission. Since the original
implementation of the nonparametric-linkage (NPL)
scoring algorithm has been shown to be overly conser-
vative when data on parental genotypes are lacking (Da-
vis and Weeks 1997; Badner et al. 1998), we decided to
compute the Kong-and-Cox (KAC) statistic (Zlr score)
as implemented in GENEHUNTER-PLUS (Kruglyak et
al. 1996; Kong and Cox 1997), using the exponential
model option, the “pairs” scoring function, and equal
weights for each family. A related program, MAP-
MAKER/SIBS (version 2.0; Kruglyak and Lander 1995),
was used to estimate the mean proportion of alleles
shared identical by descent. Allele frequencies were es-
timated from the data, and for all subanalyses, allele
frequencies were re-estimated for each data partition
examined.
Under the null hypothesis, Zlr scores have a standard
normal distribution. When the ith Zlr score from one
data partition is compared with its complementary par-
tition, the statistic
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FZ  Z Flr lrCi (1C)iD = 1/2[2(var Z ) cov Z ]lr lr
is asymptotically N(0,1). “C” and “ ” denote the1 C
two data partitions. Since all subanalyses partition the
data by family units, and since the families are indepen-
dent, the covariance term in the above expression is 0.
With one notable exception (a predicted increase in the
Zlr score of the early-age-at-onset partition for some
chromosome 1 regions), we have no prior hypotheses
about the direction of any differences that could result
from partitioning of the data. Accordingly, for the sake
of conservative consistency, all tests of the significance
of D are two tailed.
Results
Multipoint Zlr scores for all chromosomes (except the Y
chromosome) are displayed in figure 1. Five chromo-
somal regions gave nominal evidence for linkage (i.e., a
Zlr score 11.645) at two or more adjacent markers: (1)
a very broad region on 2q, extending ∼66 cM, from
D2S1391 to D2S2968; (2) a narrow region on 12p, ex-
tending ∼3.03 cM, from D12S1615 to D12S1685; (3)
a moderately sized region on 15q, extending ∼19.2 cM,
from D15S822 to the dinucleotide repeat in the actin
alpha cardiac-muscle gene; (4) a broad region on 16p,
extending ∼39.1 cM, from ATA41E04 to the centro-
mere; and (5) a moderate region on 16q, extending
∼16.8 cM, from D16S2624 to D16S3040. Table 1 re-
ports the marker at which the maximumZlr score occurs,
for each of the aforementioned five chromosomal
regions as well as the estimate of the mean proportion
of alleles shared identical by descent. Only three markers
gave nominal (i.e., ) evidence of departure fromP ! .05
Hardy-Weinberg equilibrium (GATA91H06, ;P = .006
ATA78D02, ; and D18S970, ), andP = .047 P = .049
none are located in any of the above five regions.
We preplanned three subanalyses that involved di-
chotomizing the total sample into subsets that previous
research has suggested may increase homogeneity in the
subgroups. x2 Analyses indicate that the various family
partitions are not significantly pairwise-dependent in
these data (table 2). As noted above, allele frequencies
were re-estimated whenever a new partition of the fam-
ilies was constructed. Since chromosome 16 yielded
moderate-to-strong signals for all family partitions, the
Zlr scores for this chromosome are presented separately.
It is unclear how best to report the results of a whole-
genome screen when various subgroups are analyzed
separately. The fact that these subgroup analyses were
preplanned does not mean that a price need not be paid
for performance of multiple tests. On the other hand,
for a complex and heterogeneous phenotype, such as
CaP, complete genetic characterization—including pre-
cise specification of all gene-gene and gene-environment
interactions—may require sample sizes that are an order
of magnitude larger than currently available. We have
chosen to report all adjacent markers (i.e., two or more)
for which the Zlr score is nominally significant at P !
.05. Since these P values are uncorrected for multiple
tests, most will prove to be false positives.
The first subanalysis involved partitioning the fami-
lies according to whether they met the “Hopkins” cri-
teria for “hereditary” CaP due to features of their family
history (FH). To be classified as belonging to the FH-
positive (FH) group, a family must contain either (1)
two or more brothers with a diagnosis of CaP at age
55 years, (2) at least three first-degree relatives with
a diagnosis of CaP, or (3) three consecutive generations
with CaP (Carter et al. 1992). Since our study design
required, at a minimum, the presence of at least one
affected sib pair (ASP), any family meeting criterion 3
would necessarily also meet criterion 2. Only six of the
families under study met criterion 1, and five of them
also had an affected father. Consequently, virtually all
of our FH families were so classified because they met
criterion 2. One hundred eleven families containing a
total of 199 ASPs met the criteria for FH. Table 3
reports the distribution of nominally significant Zlr
scores achieved in either partition. A number of inter-
esting contrasts are apparent.
Although no nominally significant evidence of linkage
of chromosomes 1, 3, 8, or 18 was obtained when all
of the families were analyzed together, the FH/FH
partitioning reveals such evidence. With respect to the
signals on chromosome 1, the two regions are separated
by ∼57.8 cM, so, despite their synteny, they are un-
linked. Accordingly, it is noteworthy that, for the two
blocks of adjacent chromosome 1 markers, when one
group or the other attained a nominally significant Zlr
score, the partitioning resulted in a significant difference
between the two subgroups. Of the 33 non–chro-
mosome 1 markers listed in table 3, only one, on chro-
mosome 8 (GAAT1A4), reveals a significant between-
subgroup difference.
A consistent finding in cancer genetics (Giardiello
1997) is that families with an early age at onset appear
to have higher “genetic loading” and, in some cases, a
single major locus with alleles sufficient to cause the
cancer. Therefore, we subdivided our sample according
to each family’s mean age at onset. The means were
ranked, and a median split resulted in 115 families in
each subgroup. Nominally significant Zlr scores for this
partition are reported in table 4. Interestingly, with the
exception of two contiguous markers on chromosome
12 and two contiguous markers on chromosome 15, the
highest Zlr scores are observed in the families with the
latest mean age at onset. Of the 35 markers listed in

Figure 1 Zlr scores for 420 markers genotyped on 504 brothers with CaP who were from 230 multiplex sibships. The check marks show the positions of the markers. The total length of each
chromosome (in cM) is shown in the lower-right corner.
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Table 1
Allele Sharing in ASPs, for Five Chromosomal Regions That
Yield Nominal Evidence for Linkage
Chromosome Marker
Posiiton
(cM) Zlr
Mean ASP
Allele Sharing
2q D2S2228 224.33 2.78 .557
12p D12S1685 7.67 2.00 .533
15q D15S1010 23.89 2.77 .544
16p D16S3103 32.07 2.81 .546
16q D16S3096 99.44 3.15 .563
Table 2
Distribution of Families Cross-Classified According to Criteria Used to Partition the Data
for Preplanned Subanalyses
Early Age at Onset Late Age at Onset
FH FH FH FH
CaB CaB CaB CaB CaB CaB CaB CaB
No. of families 16 41 14 44 10 44 13 48
No. of ASPs 31 67 14 44 23 78 13 48
table 4, the median split resulted in 13 (37%) significant
between-group differences in their Zlr scores. And in all
but 2 of these 13 significant differences, the linkage
signal occurs in the late-age-at-onset group.
On the basis of recent observations by Cerhan et al.
(1999), we partitioned the families according to whether
they were positive for breast cancer (CaB). To qualify
for classification within the CaB group, the proband
had to report the presence of breast cancer in a sister,
mother, biological aunt, or grandmother. These self-re-
ports were not verified. Fifty-three of the 230 multiplex
families contained one or more cases of breast cancer
(no cases of male breast cancer were reported). These
53 families contained a total of 81 ASPs. Five adjacent
markers on 1p and seven adjacent markers on 21q in
the CaB partition yielded nominally significant Zlr
scores (table 5).
The most consistent finding from our genome screen
is the suggestion of susceptibility loci on chromosome
16. Table 6 reports the Zlr scores for all 22 markers
typed on chromosome 16, both for the entire sample
and for the various partitions. It is perhaps noteworthy
that, whereas the various subgroups reported in tables
3–5 suggest a degree of chromosomal specificity, little
is evident for chromosome 16. Only for families in the
late-age-at-onset partition (and only for 16q markers)
is there an absence of even a nominally significant sig-
nal. With the exception of markers D16S539 and
D16S2621 in the early- versus late-age-at-onset com-
parison, none of the data partitions resulted in a sig-
nificant difference between any of the subgroups.
Discussion
Susceptibility loci that predispose to diseases with a late
mean age at onset are notoriously difficult to map. The
proband’s parents are usually deceased, and, even if
DNA were available on all members of the sibship, the
sibship may be too small to allow unambiguous recon-
struction of the parental genotypes. Depending on the
particulars of the disease, the proband’s offspring are
unlikely to be old enough to be informative. These dif-
ficulties certainly apply to CaP, in which the sex-limited
nature of the disease further reduces the available in-
formation. These factors help to explain why no undis-
puted susceptibility locus has yet been identified for CaP
and why it is proving so difficult to achieve unambiguous
replication in linkage studies.
We report here the results of a linkage study of 230
multiplex sibships with CaP, using a total of 420 highly
polymorphic markers. Although five different chro-
mosomal regions gave nominal evidence of a possible
susceptibility locus, none of the signals in the total sam-
ple is sufficiently strong to meet the Lander and Krug-
lyak’s (1995) threshold for “suggestive” linkage (i.e., a
or ). And, although the usefulnessP = .00074 Z ≈ 3.18lr
of this criterion has been questioned (Curtis 1996; Witte
et al. 1996), it is clear that oligogenic phenotypes—even
those with 100% heritability—may result in increased
sib-pair allele sharing that is only a few percentage
points over the null value of 50% (Suarez et al. 1994).
Linkage studies have been successful in the identifi-
cation of disease-susceptibility loci, including many that
predispose to cancer (Fearon et al. 1990; Hall et al.
1990; Groden et al. 1991; Miki et al. 1994; Tavtigian
et al. 1996). However, there are surprisingly few linkage
studies of CaP. The first and only complete genome
screen published to date was reported by Smith et al.
(1996) and presented evidence of a susceptibility locus
(HPC1 [MIM 601518]) on the long arm of chromosome
1 at 1q24-q25. A subsequent reanalysis of an expanded
collection of the multiplex pedigrees in their study sug-
gested that families with an early age at onset were
primarily responsible for the linkage signal at HPC1
(Gro¨nberg et al. 1997b, 1999). This claim remains con-
troversial. Two other studies have produced modest
support for the existence of HPC1. Cooney et al. (1997)
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Table 3
Nominally Significant KAC Zlr Scores and P Values for
Families with CaP, Subdivided According to Whether They
Are FH+ or FH5
MARKERa
POSITION
(cM)
KAC Zlr SCORE (P) IN
b
FH Families FH Families
D1S534 151.88 1.65 (.050)
D1S1653 164.09 )* 1.86 (.031)
D1S1679 170.84 )** 2.28 (.011)
D1S1677 175.62 )** 2.72 (.003)
D1S2141 233.38 2.10 (.018) )*
D1S549 239.66 1.84 (.034) )*
D2S1384 200.43 2.02 (.022)
D2S2944 210.43 2.23 (.012)
D2S434 215.78 2.15 (.016)
D2S2228 224.33 2.22 (.013)
D2S2390 225.67 1.76 (.039)
D2S1363 227.00 1.85 (.032)
D2S159 228.61 1.94 (.026)
D2S427 236.70 2.25 (.012)
D2S2968 251.94 2.25 (.012)
D2S125 260.63 1.72 (.042)
D3S4529 112.42 1.78 (.038)
D3S2459 119.09 2.15 (.016)
D3S1591 121.67 2.01 (.022)
D3S3045 124.16 1.94 (.026)
D3S1616 124.16 1.94 (.026)
D3S3695 124.83 1.73 (.042)
D8S1119 101.01 1.67 (.047)
GAAT1A4 110.20 2.36 (.009) )***
D15S822 12.30 1.80 (.036)
D15S1002 14.58 1.92 (.027)
D15S1048 19.12 1.89 (.029)
D15S165 20.24 1.65 (.050)
D15S184 21.58 1.83 (.033) 2.01 (.022)
D15S1010 23.89 2.34 (.009)
ACTC 31.46 2.74 (.003)
GATA173A03 54.40 1.87 (.031)
D18S535 64.48 1.70 (.045)
GATA81H03 66.66 1.80 (.036)
D18S970 68.30 1.94 (.026)
D18S363 71.32 2.09 (.018)
D18S851 74.93 1.95 (.025)
D18S539 74.93 1.95 (.025)
ATA82B02 106.81 1.75 (.040)
a Chromosome 16 markers are not included.
b Asterisks denote level of significance between the respective
Zlr scores of each subgroup: * = , ** =.05 1 P 1 .01 .01 1 P 1
, and *** = ..001 P ! .001
Table 4
Nominally Significant KAC Zlr Scores and P Values Families
with CaP, Subdivided by Median Age at Onset
MARKER
POSITION
(cM)
KAC Zlr SCORE (P) IN
Families with
Mean Age at
Onset in Lower
50th Percentile
Families with
Mean Age at
Onset in Upper
50th Percentile
D1S547 267.51 )* 2.06 (.020)
D1S1609 274.53 )* 2.01 (.022)
D2S2944 210.43 1.99 (.024)
D2S434 215.78 2.16 (.016)
D2S2228 224.33 2.92 (.002)
D2S2390 225.67 2.57 (.005)
D2S1363 227.00 2.35 (.009)
D2S159 228.61 2.36 (.009)
D2S427 236.70 2.16 (.015)
D2S2968 251.94 1.67 (.048)
D4S2367 78.43 )* 2.28 (.011)
D4S3243 88.35 )* 1.85 (.032)
D4S1647 104.94 )** 2.72 (.003)
D4S2623 114.04 )** 2.85 (.002)
D4S2394 129.92 )** 1.92 (.027)
ATA34E08 33.02 )*** 1.87 (.031)
D11S1392 43.16 )** 2.17 (.015)
D12S1685 7.67 1.85 (.032)
GATA49D12 17.72 1.80 (.036)
D12S2070 125.31 )** 1.65 (.050)
D12S395 136.82 )** 1.98 (.024)
D15S1002 14.58 1.65 (.049)
D15S1048 19.12 2.10 (.018)
D15S165 20.24 2.37 (.009)
D15S184 21.58 2.50 (.006)
D15S1010 23.89 3.01 (.001)
ACTC 31.46 3.00 (.001)
D15S657 104.86 1.71 (.043) )*
D15S642 122.14 1.68 (.047) )*
D21S1440 36.77 2.22 (.013)
D21S270 38.08 2.05 (.020)
D21S1255 39.22 2.06 (.020)
D21S2055 40.49 2.08 (.019)
D21S1893 43.67 2.15 (.016)
D21S266 45.87 2.12 (.017)
NOTE.—See footnotes to table 3.
reported an analysis of 59 multiplex families and ob-
tained an NPL Z-score of 1.58 ( ) at D1S466.P = .057
An analysis of the 20 families that met criteria for “he-
reditary” CaP produced an NPL Z-score of 1.72 (P =
) at D1S466. Hsieh et al. (1997) obtained equivocal.045
results in a sample of 92 multiplex families. When these
families were subdivided according to the family’s mean
age at onset, a nominally significant signal in the
younger group was detected at D1S452 (two-point
, ), and another modest signal was de-Z = 2.04 P = .023
tected at D1S2883 (two-point , ), inZ = 1.91 P = .030
the late-age-at-onset partition. Since these two markers
are only about 5.5 cM apart, these results suggest that
there could be two different CaP-susceptibility loci on
1q.
Three of the markers we typed map within the pu-
tative HPC1 region, and none approach nominal sig-
nificance in the total sample. However, nominally sig-
nificant linkage is obtained for a block of four proximal
markers in the FH partition and for two distal mark-
ers in the FH subgroup. Since our FH signal occurs
approximately 20 cM from the closest HPC1 marker,
this should not be interpreted as a replication. Three
other studies have been unable to confirm the existence
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Table 5
Nominally Significant Scores for
Families with CaP That Are CaB+
Marker
Position
(cM) Zlr (P)
D1S552 45.33 1.89 (.029)
D1S1622 56.74 3.78 (!.001)
D1S3721 72.59 2.20 (.014)
D1S2134 75.66 1.87 (.030)
D1S3728 89.49 2.37 (.009)
D21S1440 36.77 2.68 (.003)
D21S270 38.08 2.86 (.002)
D21S1255 39.22 2.83 (.002)
D21S2055 40.49 2.90 (.002)
D21S1893 43.67 2.36 (.009)
D21S266 45.87 2.21 (.013)
D21S1446 57.77 2.03 (.021)
NOTE.—See footnote “a” to table 3.
of HPC1 (McIndoe et al. 1997; Berthon et al. 1998;
Eeles et al. 1998).
Two other regions of chromosome 1 have also been
reported to harbor CaP-susceptibility loci. Berthon et
al. (1998) reported an NPL Z score of 3.1 ( )P ! .001
in the vicinity of 1q42.2-q43 in 47 French and German
families. The NPL Z score increased to 3.32 in a subset
of nine families in which the mean age at onset was !60
years. Homogeneity analysis led Berthon et al. (1998)
to estimate that this putative susceptibility locus (PCAP;
MIM 602759) accounts for !50% of the “hereditary”
CaP cases in their data. Only two markers from the
Weber 9 set map within this region, and, in our total
sample, the Zlr score is !1.0, for both markers. In our
subgroup analyses, we obtained nominally significant
evidence of linkage for these two markers—but, in the
families that we studied, the signal comes from the late-
age-at-onset partition. Recently, Gibbs et al. (1999a)
reported negative LOD scores for four markers from
this distal region of chromosome 1q, and Whittemore
et al. (1999) reported negative NPL Z-scores for the
same four markers.
In a separate report, Gibbs et al. (1999b) presented
evidence for a rare susceptibility locus, at 1p36, that
appears to be important only in families that also have
primary brain cancer. Although we did not preplan to
analyze our families according to the presence of brain
cancer, we conducted such an analysis of just chro-
mosome 1p, once the report by Gibbs et al. (1999b)
appeared. Only 13 families in our sample have a history
of brain cancer, so we have little power to confirm the
linkage. Three of the markers that we genotyped are
located in the vicinity of the signal reported by Gibbs
et al. (1999b), and, for all three markers, nonsignificant
positive Zlr scores were obtained ( , 1.15, andZ = 0.98lr
1.49 at D1S1597, D1S3669, and D1S552, respectively).
Recently, Xu et al. (1998) presented evidence of an
X-linked susceptibility locus (HPCX [MIM 300147]),
at Xq27-q28, that, they estimate, accounts for ∼16%
of “hereditary” cases of CaP. In this region, the only
X-linked marker genotyped in the sibships that we stud-
ied was GATA31E08, at Xq27.1. For the entire sample,
we obtained a multipoint Zlr score of0.163, and none
of the various data partitions produced a Zlr score
10.81.
The strongest linkage signal in our genome screen of
the entire sample occurred on the long arm of chro-
mosome 16, at 16q23.2. Analysis of the various sub-
samples indicated that no family partition dispropor-
tionately accounts for these signals. A maximum Zlr
score of 3.15 is obtained at D16S3096.
Loss of heterozygosity (LOH) studies in CaP tumors
have consistently found an increased loss on chromo-
some 16q (as well as 8p and 10q [Carter et al. 1990;
Bergerheim et al. 1991; Cher et al. 1995; Elo et al. 1997;
Osman et al. 1997]). Indeed, the pattern and distribu-
tion of LOH on 16q has led to speculation that up to
three distinct susceptibility loci important for tumori-
genesis, metastasis, or both may be present (Suzuki et
al. 1996; Latil et al. 1997). One of these regions is
located in the vicinity of our strongest signal. All pre-
vious studies of LOH in CaP tumors have been carried
out in unrelated individuals. If the moderate signal that
we have observed in these data is not a type I error,
then it raises the possibility that a proportion of the
families in our sample may be segregating an allele at
a tumor-suppressor gene in this region; and, according
to the Knudson (1971) model, all that is required to
initiate tumorigenesis is a second somatic mutation in
a single prostate cell.
Although we were able to verify the diagnosis of CaP
by histological means or medical-record review in all
but two of our subjects (and those two received treat-
ment consistent with the diagnosis), the information re-
garding a family history positive for breast cancer was
obtained from the probands, and no attempt to verify
it was made. Two genomic regions—a broad region con-
taining five markers and covering ∼45 cM on chro-
mosome 1p and a 21-cM region on chromosome
21q—yielded nominally significant Zlr scores. The Zlr
score at D1S1622 (3.78) corresponds to a LOD score
13 and meets criteria for suggestive linkage.
The short arm of chromosome 1 frequently shows
allelic loss in breast cancer tumors (Schwab et al. 1996;
Bieche et al. 1999; Perri et al. 1999). The c-myc pro-
moter–binding protein, MPB1, which suppresses tu-
morigenicity in breast cancer cells, has been mapped to
the p35-pter region of chromosome 1 (White et al.
1997). In a recent study, Millikan et al. (1999) report
frequent LOH at two 1p36 markers (D1S243 and
D1S160), but no evidence of linkage was obtained from
an analysis of families with a history of early-onset bi-
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Table 6
Chromosome 16 Multipoint KAC Zlr Scores for the Total Sample and for the Three Data Partitions
MARKER
POSITION
( cM)
KAC Zlr SCORE IN
All
Families
FH
Families
FH
Families
Families with
Early Age at Onset
Families with
Late Age at Onset
CaB
Families
ATA41E04 11.46 2.17 2.07 1.08 1.40 1.71 2.48
D16S748 22.65 2.71 1.93 1.94 1.64 2.20 2.14
D16S3062 27.05 2.34 1.65 1.71 1.16 2.16 1.99
D16S405 28.30 2.38 1.60 1.78 1.31 2.08 1.87
D16S764 29.97 2.61 1.54 2.18 1.66 2.05 1.92
ATA63G01 30.81 2.80 1.66 2.34 1.89 2.12 1.93
D16S3103 32.07 2.81 1.74 2.28 1.96 2.07 1.69
D16S403 43.89 2.37 1.43 1.86 2.08 1.20 1.10
D16S769 50.60 1.99 1.88 .90 1.70 1.05 .62
Centromere
D16S753 57.79 1.61 2.14 .16 1.16 1.04 .37
D16S3396 63.78 1.67 2.46 .04 1.28 1.12 .46
D16S3253 71.77 1.40 2.43 .38 1.26 .75 .12
GATA67G11 81.15 .95 1.92 .64 1.25 .01 .16
D16S2624 87.62 1.81 2.30 .12 2.11 .36 .93
D16S3049 97.03 2.80 2.00 1.84 2.27 1.57 1.60
D16S3096 99.44 3.15 2.06 2.30 2.82 1.56 2.08
D16S516 100.39 3.07 2.12 2.14 2.83 1.46 1.95
D16S504 101.23 3.08 2.13 2.12 2.86 1.42 2.02
D16S3040 104.45 2.48 2.23 1.19 2.62 .77 1.62
D16S402 113.52 1.48 1.44 .49 2.25 .34 1.35
D16S539 124.73 .41 .90 .48 1.97 1.53 .53
D16S2621 130.41 .82 .80 .18 2.08 1.04 .84
lateral breast cancer. Our results in the CaB partition
raise the possibility that one or more tumor-suppressor
genes capable of inhibiting tumorigenesis in both breast
and prostate cells may be located on the short arm of
chromosome 1.
As is the case with most complex diseases, polymor-
phisms in a number of candidate genes have been pro-
posed as increasing the risk for CaP. Alleles at these loci
are not believed to be necessary or sufficient to cause
CaP, any more than the Apo e4 allele is sufficient to
cause Alzheimer disease; rather, they are risk factors in
the epidemiological sense. Among these loci are the ster-
oid 5-alpha-reductase 2 gene (Reichardt et al. 1995),
on 2p23; the vitamin D–receptor gene (Taylor et al.
1996; Ingles et al. 1998), on 12q12-q14; the homeobox
3A gene (Abbaszadegan et al. 1998), on 8p21; and the
X-linked androgen-receptor (AR) gene, on Xq11-q12,
which contains in its first exon two polymorphic tri-
nucleotide repeats—a 5′ CAG repeat and a 3′ GGC re-
peat. Given the central role played by androgens in the
development and maintenance of normal prostate, and
given that the length of the CAG repeat is inversely
correlated with transcriptional activity, it is not sur-
prising that these AR polymorphisms have received a
great deal of attention. Hardy et al. (1996) found a
significant correlation between the CAG-repeat number
and an early age at onset of CaP, whereas Giovannucci
et al. (1997) found that men with shorter repeats were
at particularly high risk for distant metastatic and fatal
CaP. A recent case-control study in a French and
German sample, however, found no association between
these polymorphisms and risk for CaP (Correa-Cerro
et al. 1999). Although we did not type any of these
candidate genes, our genome screen revealed no signals
in the regions where these candidates map.
Prior to conducting any of the linkage analyses, we
preplanned to partition our sample according to vari-
ables that reasonably might produce greater homoge-
neity in the subgroups. Two of these partitions were
based on FH: families that met the Hopkins criteria for
hereditary CaP were compared with families that may
be sporadically multiplex. The second subanalysis fo-
cused on sibships from families that were CaB. The
third partitioning used age at onset to divide the families
into two equal groups according to whether the sib-
ship’s mean age at onset was below or above the
sample’s median. The use of a median split in the present
study is entirely arbitrary, since age at onset in our sam-
ple does not deviate from normality (Shapiro-and-Wilk
[1965] test; , ). For a number of well-W = .988 P = .82
known diseases, including various cancers, either strong
FH (usually with a dominant-type transmission pat-
tern) or an unusually early age at onset suggests a single
segregating susceptibility gene with high penetrance.
And, indeed, this association has been exploited suc-
cessfully to map, clone, and characterize a number of
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large-effect susceptibility loci (e.g., BRCA1 and BRCA2)
in stringently ascertained pedigrees; however, it is un-
likely that genes such as BRCA1 or BRCA2 would be
identified in a simple sib-pair study, just as it is unlikely
that any of the highly penetrant genes that give rise to
Alzheimer disease (i.e., amyloid beta A4–precursor pro-
tein, presenilin 1, or presenilin 2) would be identified
in a random sample of affected sibs. These major genes
are simply too rare. On the other hand, a genome screen
of a random sample of sib pairs concordant for Alz-
heimer disease can detect the linkage signal in the vi-
cinity of the Apo E locus on chromosome 19q, as re-
cently demonstrated by Kehoe et al. (1999).
In the two analyses that compared linkage signals
from complementary data partitions (tables 3 and 4),
additional nominally significant signals were detected
in the partitions—namely, the FH and the late-age-at-
onset partitions—that, on a priori grounds, might be
expected to yield a larger proportion of sporadic cases.
This excess could be a measure of the increased type
I–error rate occasioned by the smaller sample sizes that
result from subdivision. Alternatively, some of these sig-
nals may reflect the presence of true susceptibility loci
that exert an effect, for instance, later in life. Further
work will be required to eliminate the false-positive
signals.
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